

<b>INFORMATION DISCLOSURE STATEMENT</b> (37 CFR 1.56, 1.97, and 1.98)  SHEET 1 OF 1				ATTORNEY DOCKET	APPLICATION NO.	
				25352-0029	09/977,059	
				APPLICANT(S)		
				Prasad V.V.S.V. Manchem et al.		
				FILING DATE	GROUP	
				October 11, 2001	1617	
<b>U.S. PATENT DOCUMENTS</b>						
* EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)
<b>FOREIGN PATENT DOCUMENTS</b>						
* EX'R INITIAL	* REF. #	COUNTRY	PATENT NUMBER	DATE (MO/YR)	APPLICANT	TRANSLATION (YES/NO)
<b>OTHER DOCUMENTS</b>						
* EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)				
	17	Yarasheski et al., "Insulin resistance in HIV protease inhibitor-associated diabetes", <i>J. Acquir. Immuns Defic. Syndr.</i> , 21, 209-216 (1999)				
	18	Horn, "Postcard from Athens: Insulin resistance and more at the 3rd international workshop on lipodystrophy and adverse drug events in HIV", <i>The PRN Notebook™</i> , 6(4), 28-31 (2001), available on-line at <a href="http://www.pn.org">www.pn.org</a>				
EXAMINER'S SIGNATURE			DATE CONSIDERED			
* EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. <small>Include copy of this form in next communication to applicant.</small>						
* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 USC 120. 37 CFR 1.98(d).						